S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way

Autolus Therapeutics (AUTL) Stock Price, News & Analysis

$4.36
+0.28 (+6.86%)
(As of 12/8/2023 ET)
Compare
Today's Range
$3.90
$4.48
50-Day Range
$2.13
$4.80
52-Week Range
$1.60
$4.83
Volume
1.03 million shs
Average Volume
1.06 million shs
Market Capitalization
$758.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.17

Autolus Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
87.3% Upside
$8.17 Price Target
Short Interest
Healthy
0.85% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.08mentions of Autolus Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.99) to ($0.89) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

387th out of 933 stocks

Biological Products, Except Diagnostic Industry

64th out of 160 stocks


AUTL stock logo

About Autolus Therapeutics Stock (NASDAQ:AUTL)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

AUTL Stock Price History

AUTL Stock News Headlines

Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up to $4.08
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Autolus: CAR-T Therapy Looks Promising
See More Headlines
Receive AUTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/10/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/05/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AUTL
Fax
N/A
Employees
399
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.17
High Stock Price Target
$12.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+87.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-148,840,000.00
Pretax Margin
-3,180.50%

Debt

Sales & Book Value

Annual Sales
$6.36 million
Book Value
$1.73 per share

Miscellaneous

Free Float
129,235,000
Market Cap
$758.38 million
Optionable
Not Optionable
Beta
1.69
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Christian Martin Itin Ph.D. (Age 59)
    CEO & Director
    Comp: $2.15M
  • Dr. Martin Pule M.D. (Age 51)
    MBBS, Founder, Senior VP & Chief Scientific Officer
  • Mr. Christopher Vann (Age 58)
    Senior VP & COO
  • Mr. David Brochu (Age 67)
    Senior VP & Chief Technical Officer
  • Mr. Brent Rice (Age 57)
    Senior VP, Chief Commercial Officer & Site Head of US
  • Dr. Edgar E. W. Braendle M.D. (Age 63)
    Ph.D., Senior VP & Chief Development Officer
  • Mr. Robert F. Dolski (Age 53)
    Chief Financial Officer
  • Ms. Olivia Manser
    Director of Investor Relations
  • Dr. Chris Williams (Age 43)
    Senior Vice President of Corporate Development
  • Mr. Alexander Swan
    Chief Human Resources Officer














AUTL Stock Analysis - Frequently Asked Questions

Should I buy or sell Autolus Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AUTL shares.
View AUTL analyst ratings
or view top-rated stocks.

What is Autolus Therapeutics' stock price target for 2024?

7 analysts have issued twelve-month target prices for Autolus Therapeutics' stock. Their AUTL share price targets range from $5.00 to $12.00. On average, they anticipate the company's share price to reach $8.17 in the next twelve months. This suggests a possible upside of 87.3% from the stock's current price.
View analysts price targets for AUTL
or view top-rated stocks among Wall Street analysts.

How have AUTL shares performed in 2023?

Autolus Therapeutics' stock was trading at $1.90 at the beginning of the year. Since then, AUTL stock has increased by 129.5% and is now trading at $4.36.
View the best growth stocks for 2023 here
.

When is Autolus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our AUTL earnings forecast
.

How were Autolus Therapeutics' earnings last quarter?

Autolus Therapeutics plc (NASDAQ:AUTL) released its quarterly earnings results on Thursday, November, 2nd. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by $0.02. The firm had revenue of $0.41 million for the quarter, compared to analysts' expectations of $2 million.

What ETF holds Autolus Therapeutics' stock ?

Range Cancer Therapeutics ETF holds 44,025 shares of AUTL stock, representing 1.33% of its portfolio.

What other stocks do shareholders of Autolus Therapeutics own?
When did Autolus Therapeutics IPO?

(AUTL) raised $125 million in an initial public offering on Friday, June 22nd 2018. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

Who are Autolus Therapeutics' major shareholders?

Autolus Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (3.97%), Affinity Asset Advisors LLC (1.15%), Perpetual Ltd (1.14%), Laurion Capital Management LP (0.85%), Lynx1 Capital Management LP (0.78%) and Schonfeld Strategic Advisors LLC (0.17%).

How do I buy shares of Autolus Therapeutics?

Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AUTL) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -